1
Balkrishen Bhat, Neelima Bhat, Anne B Eldrup, Thazha P Prakash, Marija Prhavc, Quanlai Song, Phillip Dan Cook, Steven S Carroll, Malcolm Maccoss, David B Olsen: Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase of hepatitis C virus. Merck & Co, Isis Pharmaceuticals, Philippe L Durette, Melvin Winokur, August 17, 2004: US06777395 (142 worldwide citation)

The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are partic ...


2
Mcphee Fiona, Campbell Jeffrey Allen, Li Wenying, D Andrea Stanley, Zheng Zhizhen Barbara, Good Andrew Charles, Carini David J, Johnson Barry L, Scola Paul Michael: Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus. Bristol Myers Squibb Company, Mcphee Fiona, Campbell Jeffrey Allen, Li Wenying, D Andrea Stanley, Zheng Zhizhen Barbara, Good Andrew Charles, Carini David J, Johnson Barry L, Scola Paul Michael, VOLLES Warren K, November 4, 2004: WO/2004/094452 (132 worldwide citation)

Macrocyclic isoquinoline are disclosed having the general formula: A compound of formula 1: wherein R1 to R9, Q and W are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


3
Steven S Carroll, David B Olsen, Malcolm MacCoss, Balkrishen Bhat, Phillip Dan Cook, Anne B Eldrup, Thazha P Prakash: Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase. Merck & Co, Isis Pharmaceuticals, Philippe L Durette, Melvin Winokur, September 12, 2006: US07105499 (106 worldwide citation)

The present invention provides nucleoside derivatives which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of ...


4
Balkrishen Bhat, Neelima Bhat, Anne B Eldrup, Thazha P Prakash, Marija Prhavc, Quanlai Song, Phillip Dan Cook, Steven S Carroll, Malcolm Maccoss, David B Olsen: Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase. Merck & Co, Philippe L Durette, Melvin Winokur, October 24, 2006: US07125855 (103 worldwide citation)

The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are partic ...


5

6
Anne B Eldrup, Marija Prhavc, Phillip Dan Cook, Steven S Carroll, David B Olsen: Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase. Merck & Co, ISIS Pharmaceuticals, Philippe L Durette, Melvin Winokur, April 10, 2007: US07202224 (96 worldwide citation)

The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are partic ...


7

8
Rumin Zhang, Philip W Mui, Patricia C Weber: Synthetic inhibitors of hepatitis C virus NS3 protease. Schering Corporation, Jaye P McLaughlin, November 23, 1999: US05990276 (89 worldwide citation)

An inhibitor of the HCV NS3 protease. The inhibitor is a subsequence of a substrate of the NS3 protease or a subsequence of the NS4A cofactor. Another inhibitor of the present invention contains a subsequence of a substrate linked to a subsequences of the NS4A cofactor. In another embodiment the inh ...


9
COBURN CRAIG A: Inhibitors of hepatitis c virus replication. MERCK SHARP & DOHME, September 30, 2010: WO/2010/111483 (82 worldwide citation)

The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication an ...


10
Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera: Anti-HCV nucleoside derivatives. Hoffmann la Roche, George W Johnston, Dennis P Tramaloni, Lyman H Smith, December 9, 2003: US06660721 (81 worldwide citation)

The present invention comprises nucleoside derivatives for use in the treatment or prophylaxis of hepatitis C virus infections. In particular, the present invention discloses the novel use of known 2′-deoxy-2′-fluoro nucleoside derivatives as inhibitors of hepatitis C virus (HCV) RNA replication and ...